3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Neoplasms
9
Carcinoma, Hepatocellular
5
Squamous Cell Carcinoma of Head and Neck
4
Melanoma
3
Colorectal Neoplasms
3
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Head and Neck Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Sarcopenia
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Myositis
1
Metastatic Colorectal Adenocarcinoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Liver Neoplasms
1
Hyperthermia
1
Histiocytoma, Malignant Fibrous
1
Hematologic Neoplasms
1
Heart Diseases
1
Glioma
1
Eye Diseases
1
Esophageal Squamous Cell Carcinoma
1
Interventions
pembrolizumab
25
Gemcitabine
21
Nivolumab
17
Cisplatin
17
atezolizumab
14
Carboplatin
11
avelumab
9
vinflunine
7
Ipilimumab
7
Paclitaxel
6
Docetaxel
5
enfortumab vedotin
4
cabazitaxel
4
Pemetrexed
4
Mitomycin
4
cabozantinib
3
Taxes
3
Rogaratinib
3
Magnetic Resonance Spectroscopy
3
Injections
3
Albumin-Bound Paclitaxel
3
tremelimumab
2
sacituzumab govitecan
2
pemigatinib
2
niraparib
2
lenvatinib
2
bempegaldesleukin
2
apatorsen
2
XRP6258
2
Vitamin D
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Transitional Cell
×
Immune Checkpoint Inhibitors
×
Clear all
NCT03511391
2024-01-23
CHEERS
University Hospital, Ghent
Phase 2
Completed
99 enrolled